Compare TIVC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIVC | PPCB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | Australia |
| Employees | N/A | 2 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 1.9M |
| IPO Year | 2021 | N/A |
| Metric | TIVC | PPCB |
|---|---|---|
| Price | $1.40 | $0.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 86.9K | ★ 6.4M |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.75 | $0.10 |
| 52 Week High | $5.60 | $10.69 |
| Indicator | TIVC | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 41.43 |
| Support Level | $0.79 | N/A |
| Resistance Level | $2.70 | $0.13 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 100.00 | 9.76 |
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.